Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Abstract Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance bene...

Full description

Bibliographic Details
Main Authors: Angela Horvath, Florian Rainer, Mina Bashir, Bettina Leber, Bianca Schmerboeck, Ingeborg Klymiuk, Andrea Groselj-Strele, Marija Durdevic, Daniel E. Freedberg, Julian A. Abrams, Peter Fickert, Philipp Stiegler, Vanessa Stadlbauer
Format: Article
Language:English
Published: Nature Publishing Group 2019-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-019-48352-5

Internet

https://doi.org/10.1038/s41598-019-48352-5

Similar Items